Boston Scientific touts win in UK-based patent spat with Edwards Lifesciences

Boston Scientific (NYSE:BSX) said today it won a victory in a U.K.-based patent spat with Edwards Lifesciences (NYSE:EW).

The Marlborough, Mass.-based company said that the U.K. Court of Appeals dismissed an appeal from Edwards and upheld an earlier decision that its Sapien 3 infringes on a Boston Scientific patent.

In the decision, the appeals court found that all claims on the Boston Scientific patent were valid, the company said.

Boston Scientific added that it plans to appeal a U.S. Patent Office Inter Partes Review finding that certain claims of a US patent related to transcatheter heart valves owned by Boston Scientific asserted against Edwards are invalid.

Earlier this month, Edwards announced that the US Patent and Trademark Office had ruled in their favor in the patent spat.

“We are pleased with another positive ruling from the European courts which further substantiates our intellectual property. We see the U.K. court’s decision as an important validation of our patents and supports our goal to bring differentiated solutions to patients suffering from severe and symptomatic aortic valve stenosis,” corporate secretary, GC and senior VP Desiree Ralls-Morrison said in prepared remarks.

Yesterday, Boston Scientific said it is joining the Mayo Clinic and the University of Minnesota in backing startup accelerator Gener8tor as it launches a medtech focused incubator in Minneapolis.

The post Boston Scientific touts win in UK-based patent spat with Edwards Lifesciences appeared first on MassDevice.

from MassDevice https://ift.tt/2GkZrLf